COPD Trials Would Need New Endpoints Under Draft FDA Guidance; FEV Is Out
Executive Summary
Primary and secondary endpoints for Phase III studies of drugs used to treat chronic obstructive pulmonary disease should be chosen based on the drug's purported mechanism of action and the clinical indication sought, FDA says in a draft guidance
You may also be interested in...
Vaccines And Advair Keep GSK’s Earnings Steady Despite Avandia Losses
Despite losses from generic competition and falling Avandia sales, strong performances from GlaxoSmithKline's vaccines business and asthma therapy Advair kept its third quarter earnings fairly consistent with the year-ago period
Orphan Drug Czar Will Push Legislators For More Grant Funding In 2008
For the past 15 years, funding for the grants program at FDA's Office of Orphan Products Development has remained stagnant at $14 million
Shire Shuffles Corporate Leadership: CFO Russell Rises To CEO
Chairman Cavanaugh retires, to be replaced in June by former chief exec Emmens.